Reduction of TNF-a level produced by peripheral blood leukocytes of patients with COVID-19 due to treatment with chamomile ethanolic extract

Document Type : Original Article

Authors

Immunoregulation Research Center, Shahed University, Tehran, Iran

Abstract

Background and Objective: In March 2020, World Health Organization (WHO) declared 2019 coronavirus disease as a pandemic. MERS-CoV and influenza can be a valuable resource in the development of therapeutic agents for COVID-19. Matricaria chamomilla L. (chamomile) is usually useful due to its anti-inflammatory and antibacterial properties and is listed in the pharmacopoeia of 26 countries as a herbal medicine for the treatment of various disorders. This study was conducted to evaluate the potential of chamomile to reduce the level of pro-inflammatory cytokine TNF-α.
Materials and Methods: Peripheral blood mononuclear cells (PBMCs) were isolated from Covid-19 volunteers (n = 3) and treated with concentrations of 200, 300, 400, and 500 µg/ml ethanolic extract extracted from chamomile aerial parts. Tumor necrosis factor alpha (TNF-α) production levels were measured using ELISA method.
Results: Chamomile ethanolic extract (all concentrations) significantly reduced the production of pro-inflammatory cytokine TNF-α in peripheral blood cell cultures of covid-19 patients compared to the untreated group (p<0.0001).
Conclusion: The results of the present study showed for the first time that chamomile can exert its anti-inflammatory effects by reducing the level of the pro-inflammatory cytokine TNF-α, which can be attributed to the compounds of this plant with anti-inflammatory properties. As a potential alternative for the treatment of inflammatory diseases, this plant needs further investigation.

Keywords

Main Subjects


  1. Zhang Hp, Sun Yl, Wang Yf, Yazici D, Azkur D, Ogulur I, et al. Recent developments in the immunopathology of COVID‐19. Allergy. 2023;78(2):369-88.
  2. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. Journal of medical virology. 2020;92(4):424-32.
  3. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive care medicine. 2020;46(5):846-8.
  4. Blanco-Melo D, Nilsson-Payant BE, Liu W-C, Uhl S, Hoagland D, Møller R, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036-45.
  5. Sokolowska M, Lukasik ZM, Agache I, Akdis CA, Akdis D, Akdis M, et al. Immunology of COVID‐19: mechanisms, clinical outcome, diagnostics, and perspectives—a report of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy. 2020;75(10):2445-76.
  6. Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Brüggen MC, et al. Immune response to SARS‐CoV‐2 and mechanisms of immunopathological changes in COVID‐19. Allergy. 2020;75(7):1564-81.
  7. Maggi E, Azzarone BG, Canonica GW, Moretta L. What we know and still ignore on COVID‐19 immune pathogenesis and a proposal based on the experience of allergic disorders. Allergy. 2022;77(4):1114-28.
  8. Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID‐19) implicate special control measures. Journal of medical virology. 2020;92(6):568-76.
  9. Channappanavar R, Perlman S, editors. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology2017: Springer.
  10. Montazersaheb S, Hosseiniyan Khatibi SM, Hejazi MS, Tarhriz V, Farjami A, Ghasemian Sorbeni F, et al. COVID-19 infection: An overview on cytokine storm and related interventions. Virology Journal. 2022;19(1):1-15.
  11. Denaro M, Smeriglio A, Barreca D, De Francesco C, Occhiuto C, Milano G, et al. Antiviral activity of plants and their isolated bioactive compounds: An update. Phytotherapy Research. 2020;34(4):742-68.
  12. Frost R, Heinrich M, Pendry B, Bhamr S. COVID-19 and herbal medicine: A practitioner survey. European Journal of Integrative Medicine. 2021;48:101974.
  13. Habibzadeh S, Zohalinezhad ME. Antiviral activity of Matricaria chamomilla in the treatment of COVID-19: Molecular Docking study. European Journal of Integrative Medicine. 2021;48:101975.
  14. Chauhan ES, Jaya A. Chamomile an ancient aromatic plant-A review. J Ayurveda Med Sci. 2017;2(4):251-5.
  15. Srivastava JK, Gupta S. Extraction, characterization, stability and biological activity of flavonoids isolated from chamomile flowers. Molecular and cellular pharmacology. 2009;1(3):138.
  16. Rashidi R, Ghazanfari T, Radjabian T, Mirsharif ES. The effect of aqueous and ethanolic extracts of chamomile on the vital activity of peripheral blood leukocytes of patients with covid-19. Daneshvar Medicine. 2023;30(6):1-9.
  17. Al-Dabbagh B, Elhaty IA, Elhaw M, Murali C, Al Mansoori A, Awad B, et al. Antioxidant and anticancer activities of chamomile (Matricaria recutita L.). BMC research notes. 2019;12(1):1-8.
  18. Srivastava JK, Shankar E, Gupta S. Chamomile: A herbal medicine of the past with a bright future. Molecular medicine reports. 2010;3(6):895-901.
  19. Savini I, Arnone R, Catani MV, Avigliano L. Origanum vulgare induces apoptosis in human colon cancer caco2 cells. Nutrition and cancer. 2009;61(3):381-9.
  20. Chen R, Curran J, Pu F, Zhuola Z, Bayon Y, Hunt JA. In vitro response of human peripheral blood mononuclear cells (PBMC) to collagen films treated with cold plasma. Polymers. 2017;9(7):254.
  21. da Silva Antonio A, Wiedemann LSM, Veiga-Junior VF. Natural products' role against COVID-19. RSC advances. 2020;10(39):23379-93.
  22. Wu D, Lewis ED, Pae M, Meydani SN. Nutritional modulation of immune function: analysis of evidence, mechanisms, and clinical relevance. Frontiers in immunology. 2019:3160.
  23. Drummond EM, Harbourne N, Marete E, Martyn D, Jacquier JC, O'Riordan D, et al. Inhibition of proinflammatory biomarkers in THP1 macrophages by polyphenols derived from chamomile, meadowsweet and willow bark. Phytotherapy Research. 2013;27(4):588-94.
  24. Reis PEDd, Carvalho ECd, Bueno PCP, Bastos JK. Clinical application of Chamomilla recutita in phlebitis: dose response curve study. Revista latino-americana de enfermagem. 2011;19:03-10.
  25. Bhaskaran N, Shukla S, Srivastava JK, Gupta S. Chamomile: an anti-inflammatory agent inhibits inducible nitric oxide synthase expression by blocking RelA/p65 activity. International journal of molecular medicine. 2010;26(6):935-40.
  26. Srivastava JK, Pandey M, Gupta S. Chamomile, a novel and selective COX-2 inhibitor with anti-inflammatory activity. Life sciences. 2009;85(19-20):663-9.
  27. Tabet A, Boukhari A, Nouidjem Y. Phenolic content, HPLC analysis and antioxidant activity extract from Tamarix articulata. Journal of Advanced Pharmacy Education & Research. 2018;8(4).
  28. Halim C, Mirza AF, Sari MI. The Association between TNF-α, IL-6, and Vitamin D Levels and COVID-19 Severity and Mortality: A Systematic Review and Meta-Analysis. Pathogens. 2022;11(2):195.
  29. Almalki FA. Chamomile Extract Down Regulate the Expression Level of Pro-inflammatory Cytokine in PBMCs In Vitro. International Journal of Pharmaceutical Research. 2019;11(1).
  30. D’Almeida APL, de Oliveira MTP, de Souza ÉT, de Sá Coutinho D, Ciambarella BT, Gomes CR, et al. α-bisabolol-loaded lipid-core nanocapsules reduce lipopolysaccharide-induced pulmonary inflammation in mice. International journal of nanomedicine. 2017;12:4479.
  31. McKay DL, Blumberg JB. A review of the bioactivity and potential health benefits of chamomile tea (Matricaria recutita L.). Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives. 2006;20(7):519-30.
  32. Rocha NFM, Rios ERV, Carvalho AMR, Cerqueira GS, Lopes AdA, Leal LKAM, et al. Anti-nociceptive and anti-inflammatory activities of (−)-α-bisabolol in rodents. Naunyn-Schmiedeberg's archives of pharmacology. 2011;384:525-33.
  33. Harbourne N, Jacquier JC, O’Riordan D. Optimisation of the extraction and processing conditions of chamomile (Matricaria chamomilla L.) for incorporation into a beverage. Food chemistry. 2009;115(1):15-9.
  34. García-Mediavilla V, Crespo I, Collado PS, Esteller A, Sánchez-Campos S, Tuñón MJ, et al. The anti-inflammatory flavones quercetin and kaempferol cause inhibition of inducible nitric oxide synthase, cyclooxygenase-2 and reactive C-protein, and down-regulation of the nuclear factor kappaB pathway in Chang Liver cells. European journal of pharmacology. 2007;557(2-3):221-9.
  35. Liang Y-C, Huang Y-T, Tsai S-H, Lin-Shiau S-Y, Chen C-F, Lin J-K. Suppression of inducible cyclooxygenase and inducible nitric oxide synthase by apigenin and related flavonoids in mouse macrophages. Carcinogenesis. 1999;20(10):1945-52.
  36. Gerritsen ME, Carley WW, Ranges GE, Shen C-P, Phan SA, Ligon GF, et al. Flavonoids inhibit cytokine-induced endothelial cell adhesion protein gene expression. The American journal of pathology. 1995;147(2):278.
  37. Shanmugam K, Holmquist L, Steele M, Stuchbury G, Berbaum K, Schulz O, et al. Plant-derived polyphenols attenuate lipopolysaccharide-induced nitric oxide and tumour necrosis factor production in murine microglia and macrophages. Molecular nutrition & food research. 2008;52(4):427-38.
  38. Tordiman C, Coge F, Andre N, Rique H, Spedding M, Bonnet J. Characterisation of cyclooxygenase 1 and 2 expression in mouse resident peritoneal macrophages in vitro; interactions of non steroidal anti-inflammatory drugs with COX2. Biochimica et Biophysica Acta (BBA)-Lipids and Lipid Metabolism. 1995;1256(2):249-56.
  39. Rao YK, Fang S-H, Tzeng Y-M. Inhibitory effects of the flavonoids isolated from Waltheria indica on the production of NO, TNF-α and IL-12 in activated macrophages. Biological and Pharmaceutical Bulletin. 2005;28(5):912-5.
  40. Comalada M, Ballester I, Bailon E, Sierra S, Xaus J, Gálvez J, et al. Inhibition of pro-inflammatory markers in primary bone marrow-derived mouse macrophages by naturally occurring flavonoids: analysis of the structure–activity relationship. Biochemical pharmacology. 2006;72(8):1010-21.